Salarius Pharmaceuticals Inc. has entered into a merger agreement with Decoy Therapeutics Inc., where Decoy will become a wholly owned subsidiary of Salarius, with Decoy shareholders expected to own approximately 85.9% of the combined company, based on a valuation of $28 million for Decoy and $4.6 million for Salarius; the merger is contingent upon raising at least $6 million in future offerings.